This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gasche, C. Articles by Boland, C. R. Search for Related Content PubMed PubMed Citation Articles by Gasche, C. Articles by Boland, C. R. Related Collections Preclinical Intervention Preclinical Intervention: In Vitro: Drugs, Mechanisms

Mesalazine Improves Replication Fidelity in Cultured Colorectal Cells

¹ Department of Medicine 4, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria; ² Baylor University Medical Center, Dallas, Texas; and ³ Biostatistics, Cancer Center, University of California, San Diego, California

Requests for reprints: Christoph Gasche, AKH Wien, KIM4, Wahringer Gurtel 18, A-1090 Vienna, Austria. Phone: 43-1-404004764; Fax: 43-1-404004735; E-mail: christoph.gasche{at}meduniwien.ac.at.

Epidemiologic studies indicate that mesalazine has chemopreventive effects in inflammatory bowel disease–associated colorectal cancer. Most of our general understanding of chemoprevention in colorectal cancer is, however, derived from aspirin, which is structurally similar to mesalazine. Herein we determined the influence of aspirin and mesalazine on replication fidelity in cultured colorectal cells. Flow cytometry was used for quantitation of mutation rates at a (CA)₁₃ microsatellite in HCT116 cells (mismatch repair deficient) and HCT116+chr3 cells (mismatch repair proficient) that had been stably transfected with pIREShyg2-EGFP/CA13, an enhanced green fluorescence protein–based plasmid, and cultured in the absence or presence of various concentrations of aspirin or mesalazine. Aspirin at doses above 1.25 mmol/L markedly reduced cell growth. Mesalazine doses up to 5.0 mmol/L had no such effect. The mutation rate in mismatch repair–deficient HCT116 cells was 6.8 x 10^–4 ± 9.0 x 10^–5. In aspirin-treated cultures the mutation rate was 8.2 x 10^–4 ± 1.3 x 10^–4 (121% of control). Instead, mesalazine lowered the mutation rate in a dose-dependent fashion (5.5 x 10^–4 ± 1.1 x 10^–4; 81% of control). The effects of mesalazine were most significant in the M1 fraction (P < 0.0001), which represents a mutant population immediate after the polymerase error and were confirmed in mismatch repair–proficient HCT116+chr3 cells. Our data indicate that mesalazine reduces frameshift mutations at a (CA)₁₃ microsatellite in cultured colorectal cells independent of mismatch repair proficiency. This finding suggests that mesalazine improves replication fidelity, an effect that may be active in reducing mutations independent of its anti-inflammatory properties.

This article has been cited by other articles:

				M. Schwab, V. Reynders, S. Loitsch, Y. M. Shastri, D. Steinhilber, O. Schroder, and J. Stein PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells Carcinogenesis, July 1, 2008; 29(7): 1407 - 1414. [Abstract] [Full Text] [PDF]

				C. Stolfi, D. Fina, R. Caruso, F. Caprioli, M. C. Fantini, A. Rizzo, M. Sarra, F. Pallone, and G. Monteleone Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase Carcinogenesis, June 1, 2008; 29(6): 1258 - 1266. [Abstract] [Full Text] [PDF]

				C. L. Bos, S. H. Diks, J. C.H. Hardwick, K. V. Walburg, M. P. Peppelenbosch, and D. J. Richel Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/{beta}-catenin pathway activity Carcinogenesis, December 1, 2006; 27(12): 2371 - 2382. [Abstract] [Full Text] [PDF]

				A. Goel, C. Gasche, and C. R. Boland Chemoprevention Goes Gourmet: Different Flavors of NO-Aspirin Mol. Interv., August 1, 2005; 5(4): 207 - 210. [Abstract] [Full Text] [PDF]